Back to results
US 2026/0232843 A1Published application
Compositions targeting klkb1 and methods of use thereof
AssigneePoseida Therapeutics, Inc.
InventorsBlair B. MADISON, Oscar ALVAREZ
Life of this patent
Estimating the term…
Abstract
Disclosed are methods and compositions for functional genetic modifications at selected genomic sites such as KLKB1 gene. Also provided are cell populations, which comprise the functional genetic modification at one or more selected gene loci.
Claims31
A composition comprising:
- (a) a first guide RNA (gRNA) comprising a first targeting sequence set forth in SEQ ID Nos:
- 1-17, 49, 50, or 55;
- (b) a second gRNA comprising a second targeting sequence set forth in SEQ ID NOs:
- 18-34, 51, 52, or 56;
- (c) a first polynucleotide encoding a first fusion protein, wherein the first fusion protein comprises a first inactivated Cas9 domain, or nuclease domain thereof, and a first Clo051 domain, or nuclease domain thereof;
- and
- (d) a second polynucleotide encoding a second fusion protein, wherein the second fusion protein comprises a second inactivated Cas9 domain, or nuclease domain thereof, and a second Clo051 domain, or nuclease domain thereof.
4 more elements
Dependencies are inferred from the claim text.